Increases in COVID, RSV, and influenza are the result of governments refusal to enact public health measures and address ...

The Ministry of Public Health’s latest epidemiological bulletin paints a stark picture of rising respiratory infections and a ...

Respiratory syncytial virus vaccine, adjuvanted, contains recombinant glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK's proprietary AS01 E ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

MISSISSAUGA, ON, Nov. 25, 2022 /CNW/ - GSK has filed a New Drug Submission (NDS) to Health Canada for its respiratory syncytial virus (RSV) older adult vaccine candidate.

Respiratory syncytial virus is common, is quite contagious and infects most kids before their second birthday — that is, it did before the COVID-19 pandemic happened.

Background and epidemiology: Respiratory syncytial virus (RSV) is a ubiquitous paramyxovirus that infects the ciliated epithelial cells lining the airways. Nasal epithelial cells are infected ...

A NEW vaccine to protect against a serious respiratory infection is now being offered on the high street. 60 community ...

Surge in water-borne diseases, respiratory infections, and skin conditions in the IT capital, with children under two years ...

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections. RSV infection is usually mild and self-limiting but symptoms may be severe in young children, the elderly ...

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. "Respiratory ...

Discover the latest insights in the "Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025." This comprehensive report details RSV clinical trial data, including trial ...